Life-Saving Novel Agent:
A Paradigm Shift.
Combining Rapid Antiviral Action, Immune Optimization, and Tissue Regeneration in a Single, Scalable Therapeutic Approach.
arvidal (Tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine diacetate) is a synthetic peptide derived from leucine-enkephalin, poised to redefine the management of acute respiratory viral infections (ARVI). Engineered for rapid action and delivered via a 0.2% topical spray or 0.05% inhalation solution, arvidal addresses a broad spectrum of viral pathogens while uniquely preventing severe complications such as pneumonia, cytokine storm and lung damage.
ARVIDAL's Uniqueness Lies in Its Complexity and Versatility
Fast Relief and Broad Therapeutic Promise:
- Preclinical studies demonstrate ARVIDAL's ability to alleviate severe viral symptoms within 1–2 days, significantly reducing viral load and protecting the respiratory system. It exhibits >70% efficacy in lethal influenza models (H1N1, H3N2) and shows potential to reduce mortality in viral pneumonias (e.g., SARS, MERS, COVID-19).
Dual Action Mechanism:
- arvidal provides direct antiviral effects against influenza and adenoviruses through a unique replication inhibiting cAMP-mediated pathway, complemented by immune modulation.
Immune Normalization and Support:
- arvidal goes beyond fighting viruses—it intelligently empowers the immune system. It enhances phagocytosis of neutrophils and macrophages, boosts NK-cell activity, and increases early interferon production (INF-α, INF-β, INF-γ, IL-28A), while suppressing excessive proinflammatory cytokines (IL-1, IL-6, TNF-α). This balanced approach prevents cytokine storms and respiratory distress, maintaining quality of life without immune exhaustion.
Regenerative Potential:
- With cytoprotective, membrane-stabilizing, and antioxidant properties, arvidal has the potential to support lung and mucosal repair, offering a unique approach compared to existing therapies.
Cough Suppression:
- arvidal safely reduces cough intensity for 2–4 hours, improving respiratory function without affecting the central nervous system.
Established Safety Profile:
- With an LD₅₀ > 2 g/kg (IV) and no toxicity observed at 10 times the therapeutic dose, arvidal metabolizes into amino acids, delivering an unparalleled safety profile.
ARVIDAL in the current viral infections landscape
According to the World Health Organization (WHO), our world is home to approximately 300 different respiratory viral pathogens, making acute respiratory viral infections (ARVI) the most prevalent infectious diseases today. These infections, led by the notorious coronaviruses, and recurrent strains of influenza A and B, along with seasonal coronaviruses, bocaviruses, metapneumoviruses, and rhinoviruses, pose a significant and ongoing challenge to global health. Of a particular concern is the high rate of co-infections, which complicates treatment and prevention strategies. This evolving landscape of respiratory viruses demands constant vigilance and innovative healthcare solutions to protect communities worldwide.
ARVIDAL's peptide-based composition ensures an optimal physiological response, seamlessly integrating into the body's natural processes. Its breakdown into simple amino acids, which are fundamental to protein synthesis, underscores its harmonious interaction with the body's biochemistry. Building on this robust foundation of preclinical success, ARVIDAL has now secured authorization to enter phase 2 clinical trial, marking a significant milestone in its journey towards widespread medical use.
The clinical trial, entitled “Placebo-controlled double-blind randomized study for determining the optimal dose, evaluating the efficacy and safety of ARVIDAL, 0.2% topical spray, for the treatment of patients with acute respiratory viral infections, including influenza, as part of combination therapy”, is structured to rigorously assess the therapeutic potential of the spray solution in combination with existing treatments for respiratory infections, including influenza. A total of 344 patients will participate in the trial.
The clinical trial, entitled “Placebo-controlled double-blind randomized study for determining the optimal dose, evaluating the efficacy and safety of ARVIDAL, 0.2% topical spray, for the treatment of patients with acute respiratory viral infections, including influenza, as part of combination therapy”, is structured to rigorously assess the therapeutic potential of the spray solution in combination with existing treatments for respiratory infections, including influenza. A total of 344 patients will participate in the trial.
Mechanism of Action
Overall ARVIDAL possesses a unique mechanism of action: it has both direct antiviral effect and a pronounced ability to regulate the factors of local and systemic immunological defense.
Structure-based properties.
Possible therapeutic areas
Conditions for treatment with ARVIDAL
arvidal: Comprehensive Protection Against a Spectrum of Viral Threats
arvidal stands as a powerful ally in both the prevention and treatment of a wide range of viral infections. Its protective immunomodulatory activity makes it particularly effective against a range of viruses, including seasonal and pandemic influenza A and B, various types of coronaviruses (including alpha-, beta-, gamma- and deltacoronaviruses, as well as SARS-CoV and MERS coronaviruses), adenoviruses, respiratory syncytial viruses, parainfluenza, rhinoviruses, human metapneumoviruses, bocaviruses, and even infections of combined etiology.
arvidal: Your Ally in the Battle Against Pneumonia and Its complications
Can be used for treatment of complex pneumonia associated with the increasing number of combined respiratory viral infections. It plays a crucial role in averting the cytokine storm, a serious complication of these infections. Pneumonia can lead to severe lung damage, particularly pulmonary fibrosis, where lung tissue becomes irreversibly scarred, impairing lung function. Addressing this, ARVIDAL’s regenerative properties are pivotal. They significantly reduce the risk of pathological changes in the lungs, including the development of fibrotic lesions, offering a proactive approach to prevent long-term lung damage and promote tissue recovery.
Protection of the oral mucosa
Protection of the mucosa becomes increasingly crucial during epidemics. Natural age- related atrophic changes in mucous membranes, including those in the nasopharynx and throat, can lead to slower blood circulation, thinning of the epithelium, a reduction in the number of protective microvilli, and, consequently, a depression of the local immunity. As a result, a large number of viruses and allergens can lead to inflammatory changes in the nasal mucosa. arvidal stimulates the microcirculation, activates macrophages, enhances protein metabolism and the reparative capacity of tissues, exerting an immunomodulating effect.
Treatment of wounds and burns
arvidal can be used as an effective means for treating skin injuries, including burns and wounds. Due to its ability to affect various healing mechanisms, it can provide pain relief, reduce inflammation, stimulate the metabolism of skin cells, and promote recovery without scar formation.
Dosing
Final dosage form
arvidal is available in user-friendly formats to meet different needs and preferences. Available as an antiviral nasal spray, ideal for easy and effective irrigation of the mouth, throat and nose, providing direct protection where it is needed most. In addition, an inhalation solution is available, ideally administered through a nebulizer, enabling deep penetration into the lungs for comprehensive protection of the respiratory system.
Preventive measures with arvidal
Ideal for the high epidemic season, arvidal can be used to prevent SARS, minimizing the risk of infection in daily life. Regular nasopharyngeal irrigation with an easy-to-use spray helps prevent pathogens from entering the throat, trachea, and bronchi.
Spray: Your first line of defense in the early stages of infection
Easy to use and effective, especially in the early stage of infection. It protects the upper respiratory tract, which serves as the main entry point for viruses.
The solution is sprayed from the vial into each nasal passage, as well as into the back of the throat and under the tongue several times a day, for seven days.
Inhalation solution: reliable protection in the late stages of infection
The inhalation solution is specially formulated for high efficacy in the late stages of infection, targeting and protecting the lower respiratory tract. It plays a crucial role in the prevention of serious complications such as pneumonia and pulmonary fibrosis.
For inhalation, it is preferable to use a compressor-type nebulizer with a particle size of 0.5-3 micrometers. For complex treatment, inhalations should be carried out several times a day, for seven days.
For inhalation, it is preferable to use a compressor-type nebulizer with a particle size of 0.5-3 micrometers. For complex treatment, inhalations should be carried out several times a day, for seven days.
ARVIDAL was patented in USA, China, Japan, the European Union, the Eurasian Commonwealth, Russia and Nigeria. Patent applications for the national phase have been filed in Canada, Singapore, India, Indonesia, Vietnam, Korea, ARIPO countries. Patent and Trademark applications were filed in more than 40 countries.
Learn More About Intellectual Property
